Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
ENSAYO CLÍNICO RANDOMIZADO FASE II DE DOCETAXEL-CARBOPLATINO EN COMBINACIÓN CON INIPARIB (BSI-201), Y DOCETAXEL-CARBOPLATINO COMO TRATAMIENTO NEOADYUVANTE DE PACIENTES CON CÁNCER DE MAMA ESTADIO TEMPRANO Y FENOTIPO TRIPLE NEGATIVO
El objetivo principal del estudio consiste en evaluar y clasificar la actividad antitumoral, determinada por medio de la tasa de respuesta completa patológica (RCp) en la mama y en los ganglios linfát...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects
• To describe the immune response of the inactivated, split-virion swine-origin A/H1N1influenza vaccine without adjuvant in each group
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age Inmunogenicidad y seguridad de una vacuna conjugada antimeningocócica tetravalente en investigación en niños de 12 a 23 meses
1) To demonstrate the non-inferiority of the antibody response to meningococcal serogroups A, C, Y, and W after a single dose of MenACYW conjugate vaccine or Nimenrix® in toddlers who either are menin...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
TARGET GLYCEMIC CONTROL AND THE INCIDENCE OF DOCUMENTED SYMPTOMATIC HYPOGLYCEMIA IN INSULIN NAÏVE SUBJECTS WITH TYPE 2 DIABETES FAILING ON ORAL HYPOGLYCEMIC AGENT(S) AND TREATED WITH LANTUS (INSULIN GLARGINE) OR LEVEMIR (INSULIN DETEMIR): MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, COMPARATIVE, PARALLEL-GROUP STUDY
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do n...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
SARMET : Essai de phase 1 évaluant la tolérance et la dose optimale d’un inhibiteur de la protéine MET, le SAR125844, chez des patients ayant une tumeur solide avancée. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la tolérance du SAR125844, un inhibiteur de la protéine MET et de définir la dose optimale à administrer, chez des patients ayant une tumeur solide avancée. L’ét...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
study of the immunogenicity and safety of a decoy dose of HBVAXPRO®, in healthy children vaccinated 10 years ago with 3 doses of HEXAVAC® or INFANRIX®-HEXA. studio sull'immunogenicità e sulla sicurezza della dose di richiamo con HBVAXPRO®, in bambini sani vaccinati 10 prima con 3 dosi di HEXAVAC® o INFANRIX®-HEXA
*To describe, in subjects vaccinated with 3 doses of HEXAVAC® as infants, the percentage of subjects with an anti-HBs concentration ≥10 mIU/mL one month after a challenge dose of HBVAXPRO® given at le...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Étude CARD : étude randomisée de phase 4 comparant le cabazitaxel à un agent ciblant le récepteur des androgènes (abiratérone or enzalutamide) chez des patients ayant un cancer de la prostate métastatique résistant à la castration traité antérieurement avec du docétaxel et en échec rapide sous traitement par un agent ciblant le récepteur des androgènes. [essai clos aux inclusions]
La majorité des patients atteints d’un cancer de la prostate métastatique vont développer une maladie résistante à la castration. La stratégie thérapeutique pour ces patients passe par une chimiothéra...
Country
France
organs
Prostate
Specialty
Chimiothérapie
,
Hormonothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder
To evaluate the efficacy of a 100 mg fixed dose of saredutant compared to placebo in patients with major depressive disorder
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Aventis Deutschland GmbH
Update Il y a 4 ans
Efficacy and safety of intra-articular multiple doses of 500 mg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee osteoarthritis *After the clinical start of the study, an extension of the follow-up period has been established by Amendment n° 2, extending the observation period by further 26 weeks; thus, the overall study duration will become totally 39 weeks
The primary objective of the study is to compare the overall treatment effect of pain relief in the affected knee joint between icatibant and placebo in terms of daily average of general knee pain Vis...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
SANOFI AVENTIS SAVE-ONCO : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité de l’AVE5026, chez des patients ayant un cancer avec un risque élevé de thromboses veineuses. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for...
Country
France
organs
Appareil respiratoire - autres
,
Pancréas
,
Estomac
,
Côlon ou Rectum (colorectal)
,
Vessie
,
Ovaire
Specialty
Autres (cryothérapie, radiofréquence, homéopathie,...)
Essai clos aux inclusions
More information
Previous
7
8
9
10
11
12
13
14
15
16
Next